Увійти

Готові списки джерел за темами / Drug beroduat

Зміст

Статті в журналах

Добірка наукової літератури з теми "Drug beroduat"

Автор: Grafiati

Опубліковано: 7 червня 2025

Оновлено: 2 серпня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Drug beroduat".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Drug beroduat"

1

Balunov, Р. A., and A. N. Khitrov. "Pharmacoeconomic aspects of the use of bronchodilators in the management of COPD: real clinical practice." Medical Council, no. 21 (January 20, 2019): 96–104. http://dx.doi.org/10.21518/2079-701x-2018-21-96-104.

Повний текст джерела

Анотація:

Today, chronic obstructive pulmonary disease is the fourth global cause of deaths worldwide. A number of studies showed that 11 to 16 million people might suffer from the chronic obstructive pulmonary disease in Russia. The prevalence and high mortality of this disease lead to a significant socio-economic burden. A pharmacoeconomic comparison of two alternative drug technologies in the studied groups grants the reasonable opportunity to transfer patients to the domestic analogues, confirming that efficiency unit costs for using Tiotropium-native and Ipraterol-native are lower than the same cos

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Kazakov, Yu M., T. V. Nastroga, N. M. Motorna, O. E. Kitura, and N. L. Sokolyuk. "Optimised Complex Therapy of Chronic Obstructive Pulmonary Disease Exacerbation in Elderly Patients (Review)." Tuberculosis, Lung Diseases, HIV Infection, no. 2 (May 29, 2025): 101–5. https://doi.org/10.30978/tb2025-2-101.

Повний текст джерела

Анотація:

Chronic obstructive pulmonary disease (COPD) is one of the most important medical and social problems, as it ranks third among the leading causes of death worldwide. Objective — to optimise the treatment of elderly patients with COPD, GOLD II, group B, using sequential nebuliser delivery of the mucolytic drug acetylcysteine and the respiratory cytoprotector ectoine (ectobrise) against the background of basic therapy. Materials and methods. 60 elderly patients with COPD, group B, were observed. Patients in the control group (n = 30) received complex basic therapy, which included an antibacteria

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Y. M. Mostovoy, Y. M., T. V. Konstantinovych, O. R. Lindiuk, and O. V. Bugaichuk. "RECOMMENDATIONS ON COPD AND FAMILY PRACTITIONERS: WHAT IS THE LEVEL OF ADHERENCE?" Ukrainian Pulmonology Journal 29, no. 4 (2021): 15–18. http://dx.doi.org/10.31215/2306-4927-2021-29-4-15-18.

Повний текст джерела

Анотація:

Y. M. Mostovoy, T. V. Konstantinovych, O. R. Lindiuk, O. V. Bugaichuk Abstract Majority of COPD patients should receive medical care provided by family practitioners. Only the cases of severe, uncontrolled diseases must be managed by pulmonologists. That is why family practitioners must be well informed on actual requirements on diagnosis and treatment of COPD in order to give effective care to this population of patients. Following the aim to study quality of medical care, provided to COPD patients by family practitioners, we analyzed 220 out-patient records (95 men (43,2 %), 125 women (56,8

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Kirieieva, T. V., N. K. Kravchenko, and B. O. Basina. "STANDARDS FOR TREATMENT OF PATIENTS WITH COPD IN 2024: PLACE FOR TIOTROPIUM BROMIDE." Ukrainian Pulmonology Journal 32, no. 2 (2024): 55–58. http://dx.doi.org/10.31215/2306-4927-2024-32-2-55-58.

Повний текст джерела

Анотація:

Updated GOLD 2024 guidelines emphasized the problem of insufficient or inaccurate diagnosis of COPD, leading to inappropriate therapy of these patients. This trend is also widespread in Ukraine, despite the significant improvement in diagnosis and available treatment options. The aim of the study was to determine the effectiveness of tiotropium bromide (Spiriva® HandiHaler® "Boehringer Ingelheim Pharma GmbH", Germany) for the initial and follow-up treatment of patients. We evaluated the effect of the drug on the clinical and functional status of patients and adherence to therapy. Materials and

Стилі APA, Harvard, Vancouver, ISO та ін.

5

L.V., Kadomtseva, Daminov R.U., Valieva T.A., Mirzakarimova F.R., and Kaleda S.P. "USE OF NEBULIZER THERAPY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CARDIOVASCULAR COMORBIDITY." May 6, 2025. https://doi.org/10.5281/zenodo.15347598.

Повний текст джерела

Анотація:

<em>Chronic obstructive pulmonary disease (COPD) is characterized by persistent and usually progressive airflow limitation associated with various risk factors, the main one being tobacco smoking. The increasing role of this pathology among the causes of morbidity and mortality is well known. It should be noted that in recent years there has been a greater understanding of the complexity of this disease in terms of an integrated clinical assessment of severity, pathophysiology and relationship with other pathologies. Chronic obstructive pulmonary disease is a disease of the second half of life

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Zherebtsova, N. Yu, and T. V. Kajdanek. "Local and systemic adverse reactions following COVID-19 vaccine (clinical report)." Russian Journal of Infection and Immunity, May 12, 2022. http://dx.doi.org/10.15789/2220-7619-las-1817.

Повний текст джерела

Анотація:

The mass vaccination against novel coronavirus infection (COVID-19) requires to dynamically evaluate risks of adverse events following immunization to prevent them and develop vaccination tactics for various population groups. We describe a clinical case of reaction following administration of the second dose of the heterologous recombinant adenovirus based COVID-19 vaccine Gam-COVID-Vac (Sputnik V) in 48-year-old female healthcare worker. No adverse events after administration of the first dose were recorded. After vaccination, the patient complained of weakness, malaise, headache, loss of ap

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!